Clinical experience with ethacrynic acid with reference to a possible complication of the Schoenlein-Henoch type.
D002245:Carbon Dioxide / Q000097:blood; D002740:Chlorothiazide / Q000627:therapeutic use; D004357:Drug Synergism; D004976:Ethacrynic Acid / Q000009:adverse effects* / Q000627:therapeutic use*; D006333:Heart Failure / Q000188:drug therapy*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D009336:Necrosis / Q000139:chemically induced; D009941:Organomercury Compounds / Q000627:therapeutic use; D011188:Potassium / Q000652:urine; D013148:Spironolactone / Q000494:pharmacology; D014508:Urea / Q000097:blood
D009941:Organomercury Compounds; D002245:Carbon Dioxide; D013148:Spironolactone; D002740:Chlorothiazide; D014508:Urea; D004976:Ethacrynic Acid; D011188:Potassium